Table 2. Role of identified proteins in biofunctions and disorders, and canonical signaling networks.
| Biofunctions and disorders | |||
| Function/Disorder | p-Value | Higher in adults | Higher in adolescents |
| Cell-to-cell Signaling and Interaction | |||
| Synaptic transmission of synapse | 0.000033 | STXBP1,VDAC1 | SNCB,VDAC3 |
| Synaptic transmission of nervous tissue | 0.0000549 | NSF,STXBP1,VDAC1 | SNCB,VDAC3 |
| Synaptic transmission | 0.00000124 | NSF,STXBP1,VDAC1 | PPP3R1,SNCB,SYN2,VDAC3 |
| Long-term potentiation of synapse | 0.00000198 | CPLX2,VDAC1 | CALB2,CRMP1,PPP3R1, PRKCG, VDAC3 |
| Long-term potentiation | 0.00000453 | CPLX2,VDAC1 | CALB2,CRMP1,DPYSL4, PPP3R1,PRKCG,VDAC3 |
| Synaptic depression | 0.0122 | PPP3R1,PRKCG,SYN2 | |
| Cellular Morphology | p-Value | Higher in adults | Higher in adolescents |
| Size of neurons | 0.00333 | DPYSL3,GAP43,SNCB | |
| Morphology of neurites | 0.0187 | CKB | DPYSL4,GAP43 |
| Morphology of neurons | 0.00716 | CKB,DNM1 | CRMP1,DPYSL4,DPYSL5, GAP43 |
| Length of neurites | 0.00173 | DPYSL2 | DPYSL3,DPYSL4 |
| Length of neurons | 0.000214 | DPYSL2 | DBN1,DPYSL3,DPYSL4 |
| Formation of filopodia | 0.0000124 | CSRP1 | DPYSL3,DPYSL5 |
| Extension of plasma membrane projections | 0.0213 | DPYSL2 | DBN1,DPYSL5 |
| Outgrowth of neurites | 0.011 | DPYSL2,GNAO1 | DPYSL3,DPYSL5,GAP43 |
| Branching of neurons | 0.000225 | CSRP1,DPYSL2 | CRMP1,DBN1,DPYSL3,DPYSL4, GAP43 |
| Morphogenesis of neurites | 0.00276 | CSRP1,DPYSL2,SEPT2 | CRMP1,DBN1,DPYSL4,GAP43 |
| Dendritic growth/branching | 0.00244 | CSRP1 | CRMP1,DBN1,DPYSL4,GAP43 |
| Branching of neurites | 0.00125 | CSRP1,DPYSL2 | CRMP1,DBN1,DPYSL4,GAP43 |
| Morphology of cells | 0.00137 | CKB,DNM1 | CRMP1,DPYSL3,DPYSL4, DPYSL5,GAP43,SNCB |
| Size of brain | 0.0248 | CKB | FSCN1,GAP43 |
| Cellular Development | p-Value | Higher in adults | Higher in adolescents |
| Abnormal morphology of cerebral cortex | 0.00591 | CKB,CPLX2 | CRMP1,GAP43 |
| Abnormal morphology of brain | 0.0138 | CKB,CPLX2 | CRMP1,GAP43,SNCB,SYN2 |
| Abnormal morphology of nervous system | 0.0332 | CKB,CPLX2,DNM1 | CRMP1,GAP43,SNCB,SYN2 |
| Morphology of nervous system | 0.00607 | CKB,CPLX2,DNM1 | CRMP1,DPYSL4,DPYSL5, GAP43,SNCB,SYN2 |
| Proliferation of cells | 0.00297 | CSRP1,DPYSL2,GNAO1, PKM |
CFL1,DPYSL3,DPYSL5,FABP7,GAP43 |
| Proliferation of neuronal cells | 0.00476 | CSRP1,DPYSL2,GNAO1 | CFL1,DPYSL3,DPYSL5,GAP43 |
| Differentiation of cells | 0.0014 | CSRP1,DPYSL2 | CRMP1,DBN1,DPYSL3,DPYSL4, FABP7,GAP43 |
| Transport of synaptic vesicles | 0.00000475 | BIN1,CPLX2,DNM1,DPYSL2 | SNCB |
| Endocytosis of synaptic vesicles | 0.000186 | BIN1,DNM1 | SNCB |
| Growth of neurites | 0.0056 | CSRP1,DPYSL2,GNAO1 | DPYSL3,DPYSL5,GAP43 |
| Neurological Disease | p-Value | Higher in adults | Higher in adolescents |
| Neuromuscular disease | 0.000121 | CA2,CKB,ENO2 | DPYSL3,FABP7,GAP43, PPP3R1,PRKCG |
| Schizophrenia | 0.00000118 | ATP6V1B2,CSRP1,VDAC1 | CLTB,GAP43,OXCT1,PGAM1, SNCB |
| Disorder of basal ganglia | 0.000117 | CA2,CKB,ENO2 | DPYSL3,FABP7,GAP43, PPP3R1,PRKCG |
| Movement Disorders | 0.00014 | CA2,CKB,ENO2 | DPYSL3,FABP7,GAP43, PPP3R1,PRKCG |
| Huntington's Disease | 0.000119 | CA2,CKB,ENO2 | DPYSL3,FABP7,PPP3R1, PRKCG |
| Canonical pathways and upstream regulators | |||
| Pathways | p Value | Higher in adults | Higher in adolescents |
| Semaphorin Signaling in Neurons | 2.31E-08 | DPYSL2 | CRMP1,CFL1,DPYSL3,DPYSL4, DPYSL5 |
| Glycolysis I | 7.01E-07 | PKM,ENO2,GAPDH | PGAM1 |
| Huntington's Disease Signaling | 8.93E-07 | DNM1,NSF,CPLX2 | CLTA,CLTB,GNB2L1,GNB4, PRKCG |
| Androgen Signaling | 4.05E-05 | GNAO1 | CALR,GNB4,GNB2L1,PRKCG |
| Gluconeogenesis I | 4.84E-05 | ENO2,GAPDH | PGAM1 |
| Axonal Guidance Signaling | 7.26E-05 | DPYSL2,GNAO1 | GNB4,CFL1,PPP3R1,GNB2L1, DPYSL5,PRKCG |
| Regulators | |||
| MAPT | 1.15E-16 | CKB,CPLX2,DPYSL2,ENO2,GAPDH,GNAO1,PKM, STXBP1,VDAC1, |
ATP5D,CFL1,CLTA,CLTB, PGAM1,SNCB |
| APP | 3.88E-15 | CKB,CPLX2,DNM1,DPYSL2,ENO2,GAPDH,GNAO1,PKM,STXBP1,VDAC1 | ATP5D,CFL1,CLTA,CLTB,DBN1, FABP3,GAP43,PGAM1,SNCB, SYN2 |
| PSEN1 | 7.74E-14 | CKB,CPLX2,DPYSL2,ENO2,GAPDH,GNAO1,PKM, STXBP1,VDAC1 |
ATP5D,CFL1,CLTA,CLTB, PGAM1,SNCB |
| MKNK1 | 2.84E-08 | CPLX2,GNAO1,STXBP1 | CRMP1,DPYSL3,GAP43,SYN2 |
| BDNF | 6.22E-08 | CPLX2,GNAO1,STXBP1 | CALB2,CRMP1,DPYSL3,FSCN1,GAP43,SYN2 |
Proteomics results were analyzed via Ingenuity Pathway Analysis for known interactions with other proteins, signaling systems and networks in the Ingenuity Knowledge Base. Proteins that displayed higher expression during adulthood are shown on the left, and proteins that displayed higher expression during adolescence are shown on the right, as seen in Table 1. p values were derived from Ingenuity Pathway Analysis by right-tailed Fisher exact test and indicate relative overrepresentation of proteins in a given function compared with what is expected by chance.